Advertisement

Infectious disease testing company Immunetics Inc. has won a three-year, $2.4 million Phase 2 SBIR grant from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health. The funding will aid the Boston company in bringing its confirmatory test for Chagas’ disease, a potentially fatal parasitic infection, to clinical trials, Immunetics said in a news release.

The immunoblot test is designed to identify antibodies to the parasite, which occurs often in Latin America and often goes undiagnosed for years before symptoms appear. Currently, the screening tests used for Chagas’ disease rely on radioimmunoprecipitation (RIPA) to confirm screening test results – a method that Immunetics said is beyond the scope of many laboratories.

SOURCE

Advertisement
Advertisement